Printer Friendly

Tiburio Therapeutics Names Kreher as Chief Medical Officer.

M2 PHARMA-March 13, 2019-Tiburio Therapeutics Names Kreher as Chief Medical Officer

(C)2019 M2 COMMUNICATIONS

- US-based biopharmaceutical company Tiburio Therapeutics Inc has appointed Nerissa Kreher, MD, to the newly created position of chief medical officer, the company said.

Dr. Kreher brings 13 years of experience in medical affairs and clinical development from leading biotechnology companies, most recently serving as Chief Medical officer at AVROBIO, a gene therapy company.

There, she led all clinical development and clinical operations for multiple global rare disease programs, including programs for Fabry and Gaucher disease, among others.

Nerissa brings deep academic, clinical research and biotechnology industry experience and she has held leadership roles in both clinical development and medical affairs at large, public and private, start-up biotechnology companies.

Prior to AVROBIO, Dr. Kreher was the global head of clinical and medical Affairs at Zafgen, a clinical-stage biopharmaceutical company developing therapies for the treatment of metabolic diseases.

In the role, she led the clinical team responsible for advancing the development of their lead program for Prader-Willi syndrome.

Previously, she was Global Clinical Development Lead for Shire HGT and Executive Medical director of Metabolic Disorders at Alexion Pharmaceuticals.

Kreher began her career as director, Medical Affairs at Serono and medical director at Genzyme.

She received her M.D. from East Carolina University, her B.S. in biology from University of North Carolina at Chapel Hill and an M.S. in clinical research from Indiana University-Purdue University Indianapolis. Dr. Kreher holds an executive MBA from Northeastern University Graduate School of Business Administration.

Tiburio is a clinical stage biopharmaceutical company. Its pipeline consists of two clinical stage compounds, TBR-760 for the treatment of non-functioning pituitary adenoma, and TBR-065 for additional rare endocrine diseases.

The company was launched out of orphan drug accelerator Cydan with financing from leading life sciences investors, New Enterprise Associates, Longitude Capital, Lundbeckfonden Ventures, and Alexandria Venture Investments. Tiburio is located in Technology Square in Cambridge, Mass.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Mar 13, 2019
Words:332
Previous Article:Fidia Pharma USA Expands into Regenerative Medicine Markets with Launch of NuDYN.
Next Article:First Patient Dosed in Phase 1 Clinical Trial of Rocket Pharmaceuticals' RP-L102 in the US.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters